Hepatotoxicity with thiazolidinediones: is it a class effect?

Area of Science:

• Pharmacology
• Endocrinology
• Hepatology

Background:

• Decreased insulin sensitivity is a key factor in type 2 diabetes mellitus (T2DM), atherosclerosis, and cardiovascular disease.
• Glitazones (thiazolidinediones) are a class of drugs designed to target muscular insulin resistance and improve glycemic control in T2DM.
• Troglitazone, the first glitazone, was withdrawn due to severe hepatotoxicity, raising concerns about the safety of the entire drug class.

Purpose of the Study:

• To compare the efficacy and safety profiles of rosiglitazone and pioglitazone with troglitazone, focusing on hepatotoxicity.
• To evaluate whether hepatotoxicity is a class effect of glitazones or specific to troglitazone.
• To assess the cardiovascular risk profile improvements associated with glitazone therapy.

Main Methods:

• Review of clinical trials and post-marketing data for troglitazone, rosiglitazone, and pioglitazone.
• Analysis of liver enzyme levels (ALT) in patients treated with glitazones versus placebo.
• Examination of reported cases of severe hepatotoxicity and liver failure associated with each glitazone.

Main Results:

• Rosiglitazone and pioglitazone demonstrate comparable efficacy to troglitazone in reducing plasma glucose levels in T2DM.
• Incidence of significant liver enzyme elevations was similar between rosiglitazone/pioglitazone and placebo, but 3-fold higher with troglitazone.
• Few uncertain hepatotoxicity cases reported for rosiglitazone, and none for pioglitazone, contrasting with troglitazone's numerous severe cases.

Conclusions:

• Rosiglitazone and pioglitazone do not appear to share the severe hepatotoxic profile of troglitazone.
• The risk of hepatotoxicity may be specific to troglitazone, potentially due to its induction of cytochrome P450 3A4.
• While liver enzyme monitoring is recommended, current evidence supports the safety of rosiglitazone and pioglitazone for T2DM management.